Personalized therapeutics: HIV treatment in adolescents
- PMID: 18830226
- PMCID: PMC2803031
- DOI: 10.1038/clpt.2008.187
Personalized therapeutics: HIV treatment in adolescents
Erratum in
- Clin Pharmacol Ther. 2009 Jan;85(1):110
Abstract
Adolescents infected with human immunodeficiency virus (HIV) represent a heterogeneous group of pubertal children and young adults. Antiretroviral therapy (ART) in adolescents is complex and depends on multiple factors. The continued use of higher (weight- or surface-based) pediatric doses can result in potentially toxic drug exposure, whereas early introduction of lower adult doses can lead to the development of drug resistance and virologic failure. The physiological and psychosocial changes during puberty create strong grounds for an individualized therapeutic approach in HIV-infected adolescents.
Conflict of interest statement
E.V.C. is a DSMB Member of Pfizer Pharmaceuticals and a consultant for GlaxoSmithKline. The other authors declared no conflict of interest.
References
-
- UNAIDS. AIDS epidemic update: December 2007. 2008. [Accessed 11 June 2008]. < http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf>.
-
- CDC. HIV/AIDS Surveillance Report. 2006. Atlanta: US Department of Health and Human Services; 2008.
-
- American Academy of Pediatrics Committee on Pediatric AIDS, Section on International Child Health. Havens PL, Gibb DM. Increasing antiretroviral drug access for children with HIV infection. Pediatrics. 2007;119:838–845. - PubMed
-
- Grub S, et al. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 2002;71:122–130. - PubMed
-
- Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2008. [Accessed 27 June 2008]. < http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf>.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical